MD Anderson Cancer: Ribociclib Added to Endocrine Therapy Extends Survival in Postmenopausal Patients With Metastatic Breast Cancer
September 20, 2021
September 20, 2021
HOUSTON, Texas, Sept. 20 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
Longest reported overall survival benefit with a first-line CDK4/6 inhibitor in breast cancer
* * *
A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone recep . . .
* * *
Longest reported overall survival benefit with a first-line CDK4/6 inhibitor in breast cancer
* * *
A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone recep . . .